ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Harkin Withdraws Amendment Allow NIH To Bypass INDS

October 9, 1992

Sen. Dole Raps HEW Over Delays On Patent Requests

August 11, 1978

Also AIDS Malignancy Consortium grants to be consolidated on recompetition to one central group chairman’s office.

November 19, 2004

HHS To Determine Feasibility Of CHOP Evaluation

July 24, 1981

DCE Publishes Lister of Resources Available To Scientific Community

November 9, 1984

Interferon Results Cool Expectations, But Other Reports At ASCO/AACR Demonstrate Solid Progress

June 6, 1980